Programmatic Update on the use of ARVs to treat pregnant women and prevent mother-to-child transmission of HIV (PMTCT)
WHO updates HIV treatment guidance for pregnant women and preventing HIV infection in babies
With little fanfare, the World Health Organization (WHO) recently published a “Programmatic Update” on the use of antiretrovirals (ARVs) to treat pregnant women and prevent mother-to-child transmission of HIV (PMTCT) that identifies Option B and Option B plus as preferable to Option A. Both Option B and Option B+ call for the administration of triple combination antiretroviral therapy (ART) to all pregnant HIV-infected women. Under Option B, antiretroviral therapy would be stopped after the breast feeding period for women with CD4 counts above 350 while Option B + would continue ART in these women for life.